J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth
Erica Evans,Sabine Ponader,Russell Karp,Richland Wayne Tester,Michael Sheets,S. Aslanian,T. St. Martin,M. Nacht,Zhiming Zhu,Prasoon Chaturvedi,S. Witowski,H. Lounsbury,K. Stiede,Jan A. Burger,Russell C. Petter,Juswinder Singh,William F. Westlin +16 more
Journal ArticleDOI
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Tapan M. Kadia,Farhad Ravandi,Gautam Borthakur,Marina Konopleva,Courtney D. DiNardo,Naval Daver,Naveen Pemmaraju,Rashmi Kanagal-Shamanna,Xuemei Wang,Xuelin Huang,Sherry Pierce,Caitlin R. Rausch,Jan A. Burger,Alessandra Ferrajoli,Nitin Jain,Uday R. Popat,Zeev Estrov,Srdan Verstovsek,Elias Jabbour,Guillermo Garcia-Manero,Hagop M. Kantarjian +20 more
TL;DR: In this paper, the authors evaluated two lower-intensity regimens with clofarabine (n=119) or cladribine combined with low-dose cytarabines (LDAC) alternating with decitabine.
Journal ArticleDOI
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy.
Simon Schliffke,Mariela Sivina,Ekaterina Kim,Lisa von Wenserski,Benjamin Thiele,Nuray Akyüz,Clemens Falker-Gieske,Donjete Statovci,Anna Oberle,Toni Thenhausen,Artus Krohn-Grimberghe,Carsten Bokemeyer,Nitin Jain,Zeev Estrov,Alessandra Ferrajoli,William G. Wierda,Michael J. Keating,Jan A. Burger,Mascha Binder +18 more
TL;DR: Non-malignant B cell numbers declined, but patients maintained stable IGH diversity and constant fractions of IGH-mutated B cells, indicating partial preservation of antigen-experienced B cells during ibrutinib therapy, but impaired replenishment of the normal B cell pool with naïve B cells after FCR.
Journal ArticleDOI
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
Prajwal Boddu,Abdul Rashid Shah,Gautam Borthakur,Srdan Verstovsek,Guillermo Garcia-Manero,Naval Daver,Tapan M. Kadia,Farhad Ravandi,Nitin Jain,Ahmad Alhuraiji,Jan A. Burger,Steven M. Kornblau,Sherry Pierce,Sara Dellasala,Elias Jabbour,Hagop M. Kantarjian,Jorge E. Cortes +16 more
TL;DR: A retrospective review of the outcome of patients with chronic (CP) and accelerated (AP) phase CML refractory to prior TKI who discontinued ponatinib for resistance or intolerance concluded that new treatment options are required for this subset of patients.
Journal ArticleDOI
Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia
William G. Wierda,John C. Byrd,Susan O'Brien,Steven Coutre,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Jan A. Burger,Don A. Stevens,Jeff P. Sharman,Paolo Ghia,Ian W. Flinn,Cathy Zhou,Joi Ninomoto,Danelle F. James,Constantine S. Tam +15 more
TL;DR: Given that ibrutinib lead-in is predicted to reduce the tumour burden sufficiently to reduce TLS risk, current label recommendations describe TLS risk assessment based on lymph node (LN) bulk and absolute lymphocyte count (ALC) with gradual venetoclax dose ramp-up and risk-adapted prophylaxis, monitoring and treatment.